NICE:TASENICE Ltd. Analysis
Data as of 2026-08-15 - not real-time
$102.26
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
NICE Ltd. is priced at $102.26, and its moving averages give no clean directional read — the structure is neutral. Across the trailing 30 sessions it gained 5.7%. Relative strength is 54.3 — neutral — and the MACD signal is bullish. Watch $86.01 as support and $106.78 as the nearer resistance level.
Multiples put this in undervalued territory: 14.9 times earnings against the sector's 36.5. Analyst price targets sit 23.1% above the current price. Revenue is growing at 7.6% on a 13.9% profit margin.
Risk scores 6 out of 10, which is elevated for this asset class. With 30-day volatility of 56.8%, a beta of 0.19 and a maximum drawdown of 45.8%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 5/10 conviction on the long call.
Multiples put this in undervalued territory: 14.9 times earnings against the sector's 36.5. Analyst price targets sit 23.1% above the current price. Revenue is growing at 7.6% on a 13.9% profit margin.
Risk scores 6 out of 10, which is elevated for this asset class. With 30-day volatility of 56.8%, a beta of 0.19 and a maximum drawdown of 45.8%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Near-term and long-term part ways here — hold short-term against buy longer out, with 5/10 conviction on the long call.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Trading below the 200-day average of 106.63
- MACD momentum is positive
- 30-day price change of +5.7%
Medium Term
1–3 yearsPositive
Model confidence: 4/10
Key Factors
- P/E of 14.9 versus sector average of 36.5
- Trading below the 200-day average of 106.63
- Analyst targets imply +23.1% versus the current price
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- P/E of 14.9 versus sector average of 36.5
- Analyst targets imply +23.1% versus the current price
- 30-day volatility of 56.8%
Key Metrics & Analysis
Financial Health
Revenue Growth7.60%
Profit Margin13.86%
P/E Ratio14.9
ROE11.33%
ROA6.96%
Debt/Equity2.33
P/B Ratio39.8
Op. Cash Flow$672.1M
Free Cash Flow$615.3M
Industry P/E36.5
Technical Analysis
TrendNeutral
RSI54.3
Support$86.01
Resistance$106.78
MA 20$98.63
MA 50$95.14
MA 200$106.63
MACDBullish
VolumeStable
Fear & Greed Index95.98
Valuation
Fair Value$192.20
Target Price$125.85
Upside/Downside23.06%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.19
Volatility56.77%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.